GFR-话题@MedSci

#GFR#

483篇内容 | 2580人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534340, encodeId=f9751534340fa, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=重磅：肝癌在研新药FGFR4抑制剂获FDA孤儿药资格, objectType=article, longId=115959, objectId=a625115959e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a625115959e8, replyNumber=0, likeNumber=65, createdTime=2017-10-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a625115959e8, moduleTitle=重磅：肝癌在研新药FGFR4抑制剂获FDA孤儿药资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a625115959e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534339, encodeId=e8cf15343390c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, objectType=article, longId=114385, objectId=e7721143856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7721143856c, replyNumber=0, likeNumber=77, createdTime=2017-09-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7721143856c, moduleTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7721143856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534338, encodeId=6b1d1534338fb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet oncol：Dacomitinib用作携带EGFR突变的非小细胞肺癌的一线疗法的疗效和安全性。, objectType=article, longId=114247, objectId=305411424ece, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=305411424ece, replyNumber=0, likeNumber=60, createdTime=2017-09-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=305411424ece, moduleTitle=Lancet oncol：Dacomitinib用作携带EGFR突变的非小细胞肺癌的一线疗法的疗效和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=305411424ece)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534337, encodeId=5f21153433e8f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, objectType=article, longId=114074, objectId=7e4c1140e4f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4c1140e4f6, replyNumber=0, likeNumber=76, createdTime=2017-09-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4c1140e4f6, moduleTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4c1140e4f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534336, encodeId=1a2c153433626, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：FGFR1过表达肺癌原发耐药机制, objectType=article, longId=113919, objectId=e159113919ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e159113919ed, replyNumber=0, likeNumber=83, createdTime=2017-09-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e159113919ed, moduleTitle=CLIN CANCER RES：FGFR1过表达肺癌原发耐药机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e159113919ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534335, encodeId=b24b1534335cd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, objectType=article, longId=113909, objectId=a3b411390971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3b411390971, replyNumber=0, likeNumber=63, createdTime=2017-09-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3b411390971, moduleTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3b411390971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534334, encodeId=f0cd153433478, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, objectType=article, longId=112313, objectId=3530112313d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3530112313d7, replyNumber=0, likeNumber=57, createdTime=2017-09-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3530112313d7, moduleTitle=Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3530112313d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534333, encodeId=07821534333c7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=2017 澳大利亚建议：晚期非小细胞肺癌EGFR T790M检测, objectType=article, longId=112235, objectId=99941122356a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99941122356a, replyNumber=0, likeNumber=15, createdTime=2017-09-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99941122356a, moduleTitle=2017 澳大利亚建议：晚期非小细胞肺癌EGFR T790M检测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99941122356a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534332, encodeId=354c153433225, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：GABBR2可以作为EGFR19缺失肺腺癌的治疗靶点, objectType=article, longId=112037, objectId=25a711203e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25a711203e93, replyNumber=0, likeNumber=97, createdTime=2017-09-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25a711203e93, moduleTitle=CLIN CANCER RES：GABBR2可以作为EGFR19缺失肺腺癌的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25a711203e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534331, encodeId=de7f15343317e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗, objectType=article, longId=111675, objectId=74ad1116e521, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ad1116e521, replyNumber=0, likeNumber=96, createdTime=2017-09-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ad1116e521, moduleTitle=Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74ad1116e521)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534330, encodeId=8ede1534330cf, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CCLM：使用支气管肺泡灌洗液中的游离DNA 来评估EGFR突变, objectType=article, longId=111596, objectId=a5fa11159600, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5fa11159600, replyNumber=0, likeNumber=82, createdTime=2017-09-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5fa11159600, moduleTitle=CCLM：使用支气管肺泡灌洗液中的游离DNA 来评估EGFR突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5fa11159600)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534329, encodeId=f17b1534329d6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO:奥希替尼进军EGFR突变型晚期NSCLC一线治疗, objectType=article, longId=111319, objectId=f85e111319e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f85e111319e4, replyNumber=0, likeNumber=60, createdTime=2017-08-31, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f85e111319e4, moduleTitle=JCO:奥希替尼进军EGFR突变型晚期NSCLC一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f85e111319e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534328, encodeId=3a341534328e9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, objectType=article, longId=111065, objectId=5e6c111065d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e6c111065d4, replyNumber=0, likeNumber=101, createdTime=2017-08-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e6c111065d4, moduleTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6c111065d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534327, encodeId=e90e153432e44, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110822, objectId=f90d11082200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f90d11082200, replyNumber=0, likeNumber=72, createdTime=2017-08-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f90d11082200, moduleTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f90d11082200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534326, encodeId=b7221534326df, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110820, objectId=ca66110820db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca66110820db, replyNumber=0, likeNumber=73, createdTime=2017-08-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca66110820db, moduleTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca66110820db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534325, encodeId=f8a91534325f5, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：EGFR突变疫苗用于脑胶质瘤, objectType=article, longId=110688, objectId=782811068887, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782811068887, replyNumber=0, likeNumber=52, createdTime=2017-08-25, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782811068887, moduleTitle=Lancet Oncol：EGFR突变疫苗用于脑胶质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782811068887)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534324, encodeId=6689153432477, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Am J Kidney Dis：蛋白尿和eGFR对患者静脉血栓栓塞风险有何影响？, objectType=article, longId=110320, objectId=b16d11032029, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b16d11032029, replyNumber=0, likeNumber=0, createdTime=2017-08-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b16d11032029, moduleTitle=Am J Kidney Dis：蛋白尿和eGFR对患者静脉血栓栓塞风险有何影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b16d11032029)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534323, encodeId=ec4215343233a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗, objectType=article, longId=108462, objectId=42e5108462d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42e5108462d0, replyNumber=0, likeNumber=78, createdTime=2017-08-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42e5108462d0, moduleTitle=ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42e5108462d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534322, encodeId=4a141534322b0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗, objectType=article, longId=108461, objectId=a9e21084618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9e21084618a, replyNumber=0, likeNumber=51, createdTime=2017-08-12, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9e21084618a, moduleTitle=ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9e21084618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534321, encodeId=8f401534321a0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, objectType=article, longId=108175, objectId=29721081e5ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29721081e5ad, replyNumber=0, likeNumber=77, createdTime=2017-08-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29721081e5ad, moduleTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29721081e5ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

重磅：肝癌在研新药FGFR4抑制剂获FDA孤儿药资格

2017-10-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？

2017-09-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet oncol：Dacomitinib用作携带EGFR突变的非小细胞肺癌的一线疗法的疗效和安全性。

2017-09-28

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？

2017-09-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：FGFR1过表达肺癌原发耐药机制

2017-09-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药

2017-09-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：PD-L1、E-cadherin、CD24和VEGFR2是上皮癌干细胞的标记并且与快速肿瘤发生相关

2017-09-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

2017 澳大利亚建议：晚期非小细胞肺癌EGFR T790M检测

2017-09-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：GABBR2可以作为EGFR19缺失肺腺癌的治疗靶点

2017-09-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗

2017-09-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CCLM：使用支气管肺泡灌洗液中的游离DNA 来评估EGFR突变

2017-09-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO:奥希替尼进军EGFR突变型晚期NSCLC一线治疗

2017-08-31

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！

2017-08-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：EGFR突变疫苗用于脑胶质瘤

2017-08-25

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Am J Kidney Dis：蛋白尿和eGFR对患者静脉血栓栓塞风险有何影响？

2017-08-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗

2017-08-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗

2017-08-12

liuyiping (审核中...)

前往app查看评论内容

#GFR#

T790M突变检测，实现EGFR TKI耐药患者的精准治疗

2017-08-10

科室
- - 订阅+
  - 更多科室
工具
服务